Circumventing the Crabtree effect: forcing oxidative phosphorylation (OXPHOS) via galactose medium increases sensitivity of HepG2 cells to the purine derivative kinetin riboside.
Adenosine
/ pharmacology
Adenosine Triphosphate
/ metabolism
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Culture Media
Galactose
/ physiology
Glucose
/ physiology
Glycolysis
/ drug effects
Hep G2 Cells
Humans
Kinetin
/ pharmacology
Membrane Potential, Mitochondrial
/ drug effects
Neoplasms
/ metabolism
Oxidative Phosphorylation
/ drug effects
Cancer cells
Crabtree effect
Kinetin riboside
Metabolism
Mitochondria
Purine derivative
Journal
Apoptosis : an international journal on programmed cell death
ISSN: 1573-675X
Titre abrégé: Apoptosis
Pays: Netherlands
ID NLM: 9712129
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
04
09
2020
pubmed:
22
9
2020
medline:
20
8
2021
entrez:
21
9
2020
Statut:
ppublish
Résumé
Small-molecule compound-based therapies have provided new insights into cancer treatment against mitochondrial impairment. N6-furfuryladenosine (kinetin riboside, KR) is a purine derivative and an anticancer agent that selectively affects the molecular pathways crucial for cell growth and apoptosis by interfering with mitochondrial functions and thus might be a potential mitotoxicant. Metabolism of cancer cells is predominantly based on the Crabtree effect that relies on glucose-induced inhibition of cell respiration and thus on oxidative phosphorylation (OXPHOS), which supports the survival of cancer cells in metabolic stress conditions. The simplest way to circumvent this phenomenon is to replace glucose with galactose in the culture environment. Consequently, cells become more sensitive to mitochondrial perturbations caused by mitotoxicants. In the present study, we evaluated several cellular parameters and investigated the effect of KR on mitochondrial functions in HepG2 cells forced to rely mainly on OXPHOS. We showed that KR in the galactose environment is a more potent apoptosis-inducing agent. KR decreases the mitochondrial membrane potential, reduces glutathione level, depletes cellular ATP, and induces reactive oxygen species (ROS) production in the OXPHOS state, leading to the loss of cell viability. Taken together, these results demonstrate that KR directly acts on the mitochondria to limit their function and that the sensitivity of cells is dependent on their ability to cope with energetic stress.
Identifiants
pubmed: 32955614
doi: 10.1007/s10495-020-01637-x
pii: 10.1007/s10495-020-01637-x
pmc: PMC7679298
doi:
Substances chimiques
Antineoplastic Agents
0
Culture Media
0
kinetin riboside
0
Adenosine Triphosphate
8L70Q75FXE
Glucose
IY9XDZ35W2
Adenosine
K72T3FS567
Kinetin
P39Y9652YJ
Galactose
X2RN3Q8DNE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
835-852Références
J Hematol Oncol. 2014 Mar 14;7:23
pubmed: 24628795
Trends Mol Med. 2020 Jan;26(1):119-134
pubmed: 31327706
Eur J Biochem. 1993 Feb 15;212(1):95-9
pubmed: 8444168
J Bioenerg Biomembr. 2010 Feb;42(1):55-67
pubmed: 20084539
Free Radic Biol Med. 1999 Feb;26(3-4):419-30
pubmed: 9895234
Toxicol In Vitro. 2015 Jun;29(4):732-40
pubmed: 25746382
Biochem J. 1929;23(3):536-45
pubmed: 16744238
Cureus. 2018 Oct 2;10(10):e3403
pubmed: 30533337
Redox Biol. 2014 Jan 10;2:224-33
pubmed: 24494197
Bioorg Chem. 2020 Jan;94:103432
pubmed: 31776032
Nat Commun. 2016 Aug 22;7:12336
pubmed: 27545456
Annu Rev Cell Dev Biol. 2011;27:441-64
pubmed: 21985671
AIDS. 2013 Jul 31;27(12):1879-85
pubmed: 24131985
Ann N Y Acad Sci. 2000;899:349-62
pubmed: 10863552
Evid Based Complement Alternat Med. 2015;2015:527209
pubmed: 26167193
Nat Biotechnol. 2010 Mar;28(3):249-55
pubmed: 20160716
PLoS One. 2014 Sep 25;9(9):e108444
pubmed: 25254953
Cancer Commun (Lond). 2018 Oct 30;38(1):65
pubmed: 30376896
Cancer Commun (Lond). 2019 Oct 25;39(1):63
pubmed: 31653274
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180
pubmed: 28938091
Oncogenesis. 2016 Jan 18;5:e188
pubmed: 26779810
J Med Chem. 2017 Apr 27;60(8):3518-3524
pubmed: 28323427
Cancer Res. 2004 Feb 1;64(3):985-93
pubmed: 14871829
Anticancer Res. 2006 Sep-Oct;26(5A):3561-6
pubmed: 17094483
Biochem Pharmacol. 2009 Apr 1;77(7):1125-38
pubmed: 19186174
Toxicol Sci. 2007 Jun;97(2):539-47
pubmed: 17361016
Phytochemistry. 2010 Aug;71(11-12):1350-9
pubmed: 20553699
Hoppe Seylers Z Physiol Chem. 1967 Dec;348(12):1686-7
pubmed: 5586915
Cancer Res. 2012 May 15;72(10):2634-44
pubmed: 22431711
PLoS One. 2011;6(12):e28536
pubmed: 22194845
Biochim Biophys Acta. 2009 Dec;1796(2):252-65
pubmed: 19682552
Nature. 2017 Jan 12;541(7636):222-227
pubmed: 27798600
J Cell Biochem. 2011 Aug;112(8):2115-24
pubmed: 21465535
Biochim Biophys Acta. 2011 Jun;1807(6):568-76
pubmed: 20804724
Biosci Rep. 2019 Jun 14;39(6):
pubmed: 31142626
Future Med Chem. 2013 Jan;5(1):53-67
pubmed: 23256813
J Biol Chem. 2010 Mar 12;285(11):8022-30
pubmed: 20064937
Cancer Res. 2005 Aug 1;65(15):7023-30
pubmed: 16061689
FEBS J. 2007 Mar;274(6):1393-418
pubmed: 17302740
Curr Biol. 2006 Jul 25;16(14):R551-60
pubmed: 16860735
Cancer Metab. 2014 Aug 28;2:12
pubmed: 25184038
Med Hypotheses. 2012 Sep;79(3):388-92
pubmed: 22770870
Cancer Lett. 2008 Mar 8;261(1):37-45
pubmed: 18162289
J Cell Mol Med. 2003 Jan-Mar;7(1):49-56
pubmed: 12767261
J Clin Oncol. 1991 Mar;9(3):416-22
pubmed: 1671875
Biosci Rep. 2013 Nov 15;33(6):
pubmed: 24079832
Methods Enzymol. 2014;542:91-114
pubmed: 24862262
Mol Cancer Res. 2006 May;4(5):319-30
pubmed: 16687487
Trends Endocrinol Metab. 2019 Jul;30(7):412-416
pubmed: 31147164
Blood. 2012 Feb 2;119(5):1200-7
pubmed: 22160482
Front Oncol. 2018 Nov 02;8:500
pubmed: 30456204
Clin Exp Metastasis. 2011 Dec;28(8):865-75
pubmed: 21842413
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Cancer Res. 2005 Jan 15;65(2):613-21
pubmed: 15695406
Int J Biochem Cell Biol. 2016 Oct;79:128-138
pubmed: 27590850
Biochem Pharmacol. 2008 Apr 1;75(7):1451-60
pubmed: 18242582